112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders
Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market.
Conference call to discuss financial and operational results scheduled for
Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for
Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time
HENDERSON, Nev. , Aug. 5, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, was the first to demonstrate the isolation and analysis...
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market
HENDERSON, Nev. , July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating...
HENDERSON, Nev. , June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex ( TYO: 6869 ...
$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrants